

## Literatura ACTA MEDICINAE 16/2022 Farmakologická léčba

- 2 **CAR-T léčba: její možnosti a limity**  
MUDr. Štěpán Hrabovský, Ph.D. | MUDr. Flóra Kováčsová | MUDr. František Folber, Ph.D. Interní hematologická a onkologická klinika LF MU a FN Brno
- 2 **Léčba akutní myeloidní leukemie u nemocných, pro něž není vhodná intenzivní terapie – současnost a vyhlídka**  
doc. MUDr. Anna Jonášová, Ph.D. I. interní klinika – klinika hematologie VFN a 1. LF UK, Praha
- 2 **Indolentní lymfomy a jejich léčba**  
MUDr. Jan Molinský, Ph.D. I. interní klinika – klinika hematologie Všeobecné fakultní nemocnice a 1. LF UK, Praha
- 3 **Inovace v léčbě melanomu**  
MUDr. Ondřej Kodet, Ph.D. Dermatovenerologická klinika 1. LF UK a VFN, Anatomický ústav 1. LF UK, Praha; BIOCEV – Biotechnologické a biomedicínské centrum AV ČR a UK, Vestec u Prahy
- 4 **Nové cesty konzervativní léčby děložních myomů**  
doc. MUDr. Eduard Kučera, CSc. Gynekologické pracoviště Polikliniky Prahy 7
- 4 **Gastrointestinální stromální nádor – novinky v léčbě pokročilých forem**  
MUDr. Zdeněk Linke Onkologická klinika 2. LF UK a FN v Motole, Praha
- 4 **Léčebné konopí v klinické praxi**  
doc. MUDr. Jiří Slíva, Ph.D. Ústav farmakologie 3. LF UK, Praha
- 5 **Nechirurgická terapie karcinomu močového měchýře**  
MUDr. Miroslav Hodek, Ph.D. Klinika onkologie a radioterapie FN a LF UK v Hradci Králové
- 5 **Fixní kombinace aklidinium bromidu s formoteroli fumarátem v léčbě chronické obstrukční plicní nemoci**  
doc. MUDr. Jiří Slíva, Ph.D. Ústav farmakologie 3. LF UK, Praha
- 5 **Výběr inhalačních steroidů v léčbě astmatu na základě terapeutického indexu**  
MUDr. Iva Pončáková Centrum alergologie a klinické imunologie Nemocnice Na Homolce, Praha
- 6 **Farmakodynamické a farmakokinetické aspekty terapie přímými perorálními antikoagulancii**  
PharmDr. Alena Pilková | PharmDr. Jan Miroslav Hartinger, Ph.D.  
Oddělení klinické farmakologie a farmacie, Farmakologický ústav 1. LF UK a VFN, Praha
- 6 **Inzulín Toujeo jako opora každodenního života pacientů s diabetes mellitus – výsledky studie InRange a ULTRAFLEXI1**  
MUDr. Kateřina Himmelová, MBA Diabetologie-endokrinologie Hi-dent, s. r. o., Ostrava  
Mgr. Petr Srnec, MBA Fakulta tělesné kultury, Katedra přírodních věd v kinantropologii, Univerzita Palackého, Olomouc
- 7 **Potenciál fixních kombinací nejen v diabetologii se zaměřením na empagliflozin**  
doc. MUDr. Jiří Slíva, Ph.D. Ústav farmakologie 3. LF UK, Praha
- 7 **Ixekizumab – význam v léčbě axiální spondyloartrity**  
MUDr. Olga Kryštůfková, Ph.D. Revmatologický ústav, Praha

# CAR-T léčba: její možnosti a limity

MUDr. Štěpán Hrabovský, Ph.D. | MUDr. Flóra Kováčová | MUDr. František Folber, Ph.D. Interní hematologická a onkologická klinika LF MU a FN Brno

- 1 Folber, F. – Kováčová, F. – Horáček, J. M., et al.: CAR-T terapie v České republice. *Farmakoterapie*, 2022, 18, suppl. 2, s. 36–40.
- 2 Marofi, F. – Motavalli, R. – Safonov, V. A., et al.: CART cells in solid tumors: challenges and opportunities. *Stem Cell Res Ther*, 2021, 12, s. 81.
- 3 Monjezi, R. – Miskey, C. – Gogishvili, T., et al.: Enhanced CAR T-cell engineering using non-viral Sleeping Beauty transposition from minicircle vectors. *Leukemia*, 2017, 31, s. 186–194.
- 4 Harris, E. – Elmer, J. J.: Optimization of electroporation and other non-viral gene delivery strategies for T cells. *Biotechnol Prog*, 2021, 37, s. e3066.
- 5 Pasquini, M. C. – Hu, Z.-H. – Curran, K., et al.: Real-world evidence of tisagenlecleucel for pediatric acute lymphoblastic leukemia and non-Hodgkin lymphoma. *Blood Adv*, 2020, 21, s. 5414–5424.
- 6 Nastoupil, L. J. – Jain, M. D. – Feng, L., et al.: Standard-of-care axi-cabtagene ciloleucel for relapsed or refractory large B-cell lymphoma: results from the US lymphoma CART consortium. *J Clin Oncol*, 2020, 38, s. 3119–3128.
- 7 Folber, F. – Pytlík, R. – Polgárová, K., et al.: Chimeric antigen receptor T-cell therapy in the Czech republic. *EBMT*, 2022, 48, s. P110.
- 8 Jacobson, C. A. – Chavez, J. C. – Sehgal, A. R., et al.: Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trial. *Lancet Oncol*, 2022, 23, s. 91–103.
- 9 Fowler, N. H. – Dickinson, M. – Dreyling, M., et al.: Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial. *Nat Med*, 2022, 28, s. 325–332.
- 10 Wang, Y. – Jain, P. – Locke, F. L., et al.: Brexucabtagene autoleucel for relapsed/refractory mantle cell lymphoma: real world experience from the US Lymphoma CART Consortium. *Blood*, 2021, 138, suppl. 1, s. 744.

# Léčba akutní myeloidní leukemie u nemocných, pro něž není vhodná intenzivní terapie – současnost a vyhlídka

doc. MUDr. Anna Jonášová, Ph.D. I. interní klinika – klinika hematologie VFN a 1. LF UK, Praha

- 1 Cancer Stat Facts: leukemia – acute myeloid leukemia (AML). National Cancer Institute; Surveillance, Epidemiology, and Results Program. 2022. Dostupné z: <https://seer.cancer.gov/statfacts/html/aml.html>, vyhledáno 7. 11. 2022.
- 2 Vespa, J. – Medina, L. – Armstrong, D. M.: Demographic Turning Points for the United States: Population Projections for 2020 to 2060. United States Census Bureau. 2020. Dostupné z: <https://www.census.gov/library/publications/2020/demo/p25-1144.html>, vyhledáno 7. 11. 2022.
- 3 Kantarjian, H. – Kadia, T. – DiNardo, C., et al.: Acute myeloid leukemia: current progress and future directions. *Blood Cancer J*, 2021, 11, s. 41.
- 4 Appelbaum, F. R. – Gundacker, H. – Head, D. R., et al.: Age and acute myeloid leukemia. *Blood*, 2006, 107, s. 3481–3485.
- 5 Wass, M. – Hitz, F. – Schaffrath, J., et al.: Value of different comorbidity indices for predicting outcome in patients with acute myeloid leukemia. *PLoS One*, 2016, 11, s. e0164587.
- 6 Rossi, G. – Pelizzari, A. M. – Bellotti, D., et al.: Cytogenetic analogy between myelodysplastic syndrome and acute myeloid leukemia of elderly patients. *Leukemia*, 2000, 14, s. 636–641.
- 7 Papaemmanuil, E. – Gerstung, M. – Bullinger, L., et al.: Genomic classification and prognosis in acute myeloid leukemia. *N Engl J Med*, 2016, 374, s. 2209–2221.
- 8 Dombret, H. – Seymour, J. F. – Butrym, A., et al.: International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with > 30% blasts. *Blood*, 2015, 126, s. 291–299.
- 9 DiNardo, C. D. – Jonas, B. A. – Pullarkat, V., et al.: Azacitidine and venetoclax in previously untreated acute myeloid leukemia. *N Engl J Med*, 2020, 383, s. 617–629.
- 10 DiNardo, C. D. – Pratz, K. – Pullarkat, V., et al.: Venetoclax combined with decitabine or azacitidine in treatment-naïve, elderly patients with acute myeloid leukemia. *Blood*, 2019, 133, s. 7–17.
- 11 Cherry, E. – Abbott, D. – Amaya, M., et al.: Venetoclax and azacitidine compared to induction chemotherapy for newly diagnosed patients with acute myeloid leukemia. *Blood*, 2021, 5, s. 5565–5573.
- 12 Juliusson, G.: Older patients with acute myeloid leukemia benefit from intensity chemotherapy: an update from the Swedish Acute Leukemia Registry. *Clin Lymphoma Myeloma Leuk*, 2011, 11, suppl. 1, s. S54–S59.
- 13 Wei, A. H. – Strickland, S. A. Jr. – Hou, J. Z., et al.: Venetoclax combined with low-dose cytarabine for previously untreated patients with acute myeloid leukemia: results from a phase Ib/II study. *J Clin Oncol*, 2019, 37, s. 1277–1284.
- 14 Sallman, D. – Kambhampati, S. – Al Malki, M., et al.: AML-196: the first-in-class anti-CD47 antibody magrolimab in combination with azacitidine is well tolerated and effective in AML patients: phase 1b results. *Clinical Lymphoma Myeloma and Leukemia*, 2021, 21, s. 290.
- 15 David, A. – Sallman, R. S. K. – De Zern, A. E., et al.: Long term follow-up and combined phase 2 results of eprentapopt (APR-246) and azacitidine (AZA) in patients with TP53 mutant myelodysplastic syndromes (MDS) and oligoblastic acute myeloid leukemia (AML). *Blood*, 2021, 138, s. 246.
- 16 Uy, G. L. – Aldoss, I. – Foster, M. C., et al.: Flotetuzumab as salvage immunotherapy for refractory acute myeloid leukemia. *Blood*, 2021, 137, s. 751–762.
- 17 Stein, E. M. – Aldoss, I. – DiPersio, J. F., et al.: Safety and efficacy of menin inhibition in patients (Pts) with MLL-rearranged and NPM1 mutant acute leukemia: a phase (Ph) 1, first-in-human study of SNDX-5613 (AUGMENT 101). *Blood*, 2021, 138, suppl. 1, s. 699.
- 18 Fukushima, N. – Minami, Y. – Kakiuchi, S., et al.: Small-molecule Hedgehog inhibitor attenuates the leukemia-initiation potential of acute myeloid leukemia cells. *Cancer Sci*, 2016, 107, s. 1422–1429.
- 19 Cortes, J. E. – Heidel, F. H. – Hellmann, A., et al.: Randomized comparison of low dose cytarabine with or without glasdegib in patients with newly diagnosed acute myeloid leukemia or high-risk myelodysplastic syndrome. *Leukemia*, 2019, 33, s. 379–389.
- 20 Pollyea, D. A. – Dinardo, C. D. – Arellano, M. L., et al.: 461 results of venetoclax and azacitidine combination in chemotherapy ineligible untreated patients with acute myeloid leukemia with IDH1/2 mutations. *Blood*, 2020, 136, suppl. 1, s. 5–7.
- 21 Konopleva, M. – Thirman, M. J. – Pratz, K. W., et al.: Impact of FLT3 mutation on outcomes after venetoclax and azacitidine for patients with treatment-naïve acute myeloid leukemia. *Clin Cancer Res*, 2022, 28, s. 2744–2752.
- 22 Maiti, A. – DiNardo, C. D. – Daver, N. G., et al.: Triplet therapy with venetoclax, FLT3 inhibitor and decitabine for FLT3-mutated acute myeloid leukemia. *Blood Cancer J*, 2021, 11, s. 25.
- 23 Wei, A. H. – Dohner, H. – Pocock, C., et al.: Oral azacitidine maintenance therapy for acute myeloid leukemia in first remission. *N Engl J Med*, 2020, 383, s. 2526–2537.

# Indolentní lymfomy a jejich léčba

MUDr. Jan Molínský, Ph.D. I. interní klinika – klinika hematologie Všeobecné fakultní nemocnice a 1. LF UK, Praha

- 1 Wilder, R. B. – Jones, D. – Tucker, S. L., et al.: Long-term results with radiotherapy for stage I-II follicular lymphomas. *Int J Radiat Oncol Biol Phys*, 2001, 51, s. 1219–1227.
- 2 Ruella, M. – Filippi, A. R. – Bruna, R., et al.: Addition of rituximab to involved-field radiation therapy prolongs progression-free survival in stage I-II follicular lymphoma: Results of a multicenter study. *Int J Radiat Oncol Biol Phys*, 2016, 15, 94, s. 783–791.
- 3 Macmanus, M. – Fisher, R. – Roos, D., et al.: Randomized trial of systemic therapy after involved-field radiotherapy in patients with early-stage follicular lymphoma: TROG 99.03. *J Clin Oncol*, 2018, 36, s. 2918–2925.
- 4 Advani, R. – Rosenberg, S. A. – Horning, S. J.: Stage I and II follicular non-Hodgkin's lymphoma: Long-term follow-up of no initial therapy. *J Clin Oncol*, 2004, 22, s. 1454–1459.
- 5 Friedberg, J. W. – Byrtek, M. – Link, B. K., et al.: Effectiveness of first-line management strategies for stage I follicular lymphoma: Analysis of the National Lymphocare Study. *J Clin Oncol*, 2012, 30, s. 3368–3375.
- 6 Ardesna, K. – Smith, P. – Norton, A., et al.: Long-term effect of a watch and wait policy vs immediate systemic treatment for asymptomatic advanced-stage non-Hodgkin lymphoma: a randomised controlled trial. *Lancet*, 2003, 362, s. 516–522.
- 7 Brice, P. – Bastion, Y. – Lepage, E., et al.: Comparison in low-tumour-burden follicular lymphomas between an initial no-treatment policy, prednimustine, or interferon alfa: a randomized study from the Groupe d'Etude des Lymphomes Folliculaires. *Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol*, 1997, 15, s. 1110–1117.
- 8 Ardesna, K. M. – Qian, W. – Smith, P., et al.: Rituximab versus a watch-and-wait approach in patients with advanced-stage, asymptomatic, non-bulky follicular lymphoma: An open-label randomised phase 3 trial. *Lancet Oncol*, 2014, 15, s. 424–435.
- 9 Kahl, B. S. – Hong, F. – Williams, M. E., et al.: Rituximab extended schedule or re-treatment trial for low-tumor burden follicular lymphoma: Eastern cooperative oncology group protocol E4402. *J Clin Oncol*, 2014, 32, s. 3096–3102.
- 10 Hiddemann, W. – Kneba, M. – Dreyling, M., et al.: Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. *Blood*, 2005, 106, s. 3725–3732.
- 11 Marcus, R. – Imrie, K. – Solal-Celigny, P., et al.: Phase III study of R-CVP compared with cyclophosphamide, vincristine, and prednisone alone in patients with previously untreated advanced follicular lymphoma. *J Clin Oncol*, 2008, 26, s. 4579–4586.
- 12 Marcus, R. – Davies, A. – Ando, K., et al.: Obinutuzumab for the first-line treatment of follicular lymphoma. *N Engl J Med*, 2017, 377, s. 1331–1344.
- 13 Rummel, M. J. – Niederle, N. – Maschmeyer, G., et al.: Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial. *Lancet*, 2013, 381, s. 1203–1210.
- 14 Flinn, I. W. – van der Jagt, R. – Kahl, B. S., et al.: Randomized trial of bendamustine-rituximab or R-CHOP/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study. *Blood*, 2014, 123, s. 2944–2952.
- 15 Salles, G. – Seymour, J. F. – Offner, F., et al.: Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial. *Lancet*, 2011, 377, s. 42–51.
- 16 Ghielmini, M. – Schmitz, S. F. H. – Cogliatti, S. B., et al.: Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly x 4 schedule. *Blood*, 2004, 103, s. 4416–4423.
- 17 Sehn, L. H. – Chua, N. – Mayer, J., et al.: Obinutuzumab plus bendamustine versus bendamustine monotherapy in patients with rituximab-refractory indolent non-Hodgkin lymphoma (GADOLIN): a randomised, controlled, open-label, multicentre, phase 3 trial. *Lancet Oncol*, 2016, 17, s. 1081–1093.
- 18 Leonard, J. P. – Jung, S. H. – Johnson, J., et al.: Randomized trial of lenalidomide alone versus lenalidomide plus rituximab in patients with recurrent follicular lymphoma: CALGB 50401 (Alliance). *J Clin Oncol*, 2015, 33, s. 3635–3640.
- 19 van Oers, M. H. J. – van Glabbeke, M. – Giurgea, L., et al.: Rituximab maintenance treatment of relapsed/resistant follicular non-Hodgkin's lymphoma: Long-term outcome of the EORTC 20981 phase III randomized intergroup study. *J Clin Oncol*, 2010, 28, s. 2853–2858.
- 20 Ghione, P. – Cavallo, F. – Visco, C., et al.: A retrospective study of R-DHAP/Ox for early progressing follicular lymphoma. *Br J Haematol*, 2018, 183, s. 828–831.
- 21 Schouten, H. C. – Qian, W. – Kvaloy, S., et al.: High-dose therapy improves progression-free survival and survival in relapsed follicular non-Hodgkin's lymphoma: results from the randomized European CUP Trial. *J Clin Oncol*, 2003, 21, s. 3918–3927.

- 22 Gopal, A. K. – Kahl, B. S. – de Vos, S., et al.: PI3K $\delta$  inhibition by idelalisib in patients with relapsed indolent lymphoma. *N Engl J Med*, 2014, 370, s. 1008–1018.
- 23 Flinn, I. W. – Miller, C. B. – Ardeshna, K. M., et al.: DYNAMO: A phase II study of duvelisib (IPI-145) in patients with refractory indolent non-Hodgkin lymphoma. *J Clin Oncol*, 2019, 37, s. 912–922.
- 24 Jacobson, C. A. – Chavez, J. C. – Sehgal, A. R., et al.: Axicabtagene Ciloleucelel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trial. *Lancet Oncol*, 2022, 23, s. 91–103.
- 25 Fowler, N. H. – Dickinson, M. – Dreyling, M., et al.: Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial. *Nat Med*, 2022, 28, s. 325–332.
- 26 Hallek, M. – Cheson, B. D. – Catovsky, D., et al.: Special report iw-CLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL. *Blood*, 2018, 131, s. 2745–2760.
- 27 Thompson, P. A. – Tam, C. S. – O'Brien, S. M., et al.: Fludarabine, cyclophosphamide, and rituximab treatment achieves long-term disease-free survival in IGHV-mutated chronic lymphocytic leukemia. *Blood*, 2016, 127, s. 303–309.
- 28 Fischer, K. – Al-Sawaf, O. – Bahlo, J., et al.: Venetoclax and obinutuzumab in patients with CLL and coexisting conditions. *N Engl J Med*, 2019, 380, s. 2225–2236.
- 29 Woyach, J. A. – Ruppert, A. S. – Heerema, N. A., et al.: Ibrutinib regimens versus chemoimmunotherapy in older patients with untreated CLL. *N Engl J Med*, 2018, 379, s. 2517–2528.
- 30 Shanafelt, T. D. – Wang, X. – Kay, N. E., et al.: Ibrutinib–rituximab or chemoimmunotherapy for chronic lymphocytic leukemia. *N Engl J Med*, 2019, 381, s. 432–443.
- 31 Sharman, J. P. – Egyed, M. – Jurczak, W., et al.: Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzumab for treatment-naïve chronic lymphocytic leukaemia (ELEVATE-TN): a randomised, controlled, phase 3 trial. *Lancet*, 2020, 395, s. 1278–1291.
- 32 Byrd, J. C. – Brown, J. R. – O'Brien, S., et al.: Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. *N Engl J Med*, 2014, 371, s. 213–223.
- 33 Furman, R. R. – Sharman, J. P. – Coutre, S. E., et al.: Idelalisib and rituximab in relapsed chronic lymphocytic leukemia. *N Engl J Med*, 2014, 370, s. 997–1007.
- 34 Ghia, P. – Pluta, A. – Wach, M., et al.: ASCEND: phase III, randomized trial of acalabrutinib versus idelalisib plus rituximab or bendamustine plus rituximab in relapsed or refractory chronic lymphocytic leukemia. *J Clin Oncol*, 2020, 38, s. 2849–2861.
- 35 Byrd, J. C. – Hillmen, P. – Ghia, P., et al.: Acalabrutinib versus ibrutinib in previously treated chronic lymphocytic leukemia: results of the first randomized phase III trial. *J Clin Oncol*, 2021, 39, s. 3441–3452.
- 36 Seymour, J. F. – Kipps, T. J. – Eichhorst, B., et al.: Venetoclax–rituximab in relapsed or refractory chronic lymphocytic leukemia. *N Engl J Med*, 2018, 378, s. 1107–1120.
- 37 Zullo, A. – Hassan, C. – Cristofari, F., et al.: Effects of Helicobacter pylori eradication on early stage gastric mucosa-associated lymphoid tissue lymphoma. *Clin Gastroenterol Hepatol*, 2010, 8, s. 105–110.
- 38 Zucca, E. – Arcaini, L. – Buske, C., et al.: Marginal zone lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Ann Oncol*, 2020, 31, s. 17–29.
- 39 Zucca, E. – Conconi, A. – Martinelli, G., et al.: Final results of the IELSG-19 randomized trial of mucosa-associated lymphoid tissue lymphoma: improved event-free and progression-free survival with rituximab plus chlorambucil versus either chlorambucil or rituximab monotherapy. *J Clin Oncol*, 2017, 35, s. 1905–1912.
- 40 Salar, A. – Domingo-Domenech, E. – Panizo, C., et al.: First-line response-adapted treatment with the combination of bendamustine and rituximab in patients with mucosa-associated lymphoid tissue lymphoma (MALT2008-01): a multicentre, single-arm, phase 2 trial. *Lancet Haematol*, 2014, 1, s. e104–e111.
- 41 Kalpadakis, P. – Pangalis, G. A. – Sachanas, S., et al.: Rituximab monotherapy in splenic marginal zone lymphoma: prolonged responses and potential benefit from maintenance. *Blood*, 2018, 132, s. 666–670.

## Inovace v léčbě melanomu

MUDr. Ondřej Kodet, Ph.D. Dermatovenerologická klinika 1. LF UK a VFN, Anatomický ústav 1. LF UK, Praha;

BIOCEV – Biotechnologické a biomedicínské centrum AV ČR a UK, Vestec u Prahy

- 1 Weber, J. S.: Immunotherapy in the adjuvant setting for high-risk melanoma. *Clin Adv Hematol Oncol*, 2018, 16, s. 546–548.
- 2 Lens, M. – Ferrucci, P. F. – Testori, A.: Anti-CTLA4 monoclonal antibody ipilimumab in the treatment of metastatic melanoma: recent findings. *Recent Pat Anticancer Drug Discov*, 2008, 3, s. 105–113.
- 3 Ribas, A. – Kirkwood, J. M. – Flaherty, K. T.: Anti-PD-1 antibody treatment for melanoma. *Lancet Oncol*, 2018, 19, s. e219.
- 4 Bhandaru, M. – Rotte, A.: Monoclonal antibodies for the treatment of melanoma: Present and future strategies. *Methods Mol Biol*, 2019, 1904, s. 83–108.
- 5 Eggermont, A. M. M. – Chiarion-Sileni, V. – Grob, J. J., et al.: Adjuvant ipilimumab versus placebo after complete resection of stage III melanoma: long-term follow-up results of the European Organisation for Research and Treatment of Cancer 18071 double-blind phase 3 randomised trial. *Eur J Cancer*, 2019, 119, s. 1–10.
- 6 Weber, J. – Mandal, M. – Del Vecchio, M., et al.: Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma. *N Engl J Med*, 2017, 377, s. 1824–1835.
- 7 Eggermont, A. M. M. – Chiarion-Sileni, V. – Grob, J. J., et al.: Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): A randomised, double-blind, phase 3 trial. *Lancet Oncol*, 2015, 16, s. 522–530.
- 8 Haydn, J. M. – Hufnagel, A. – Grimm, J., et al.: The MAPK pathway as an apoptosis enhancer in melanoma. *Oncotarget*, 2014, 5, s. 5040–5053.
- 9 Maio, M. – Lewis, K. – Demidov, L., et al.: Adjuvant vemurafenib in resected, BRAFV600 mutation-positive melanoma (BRIM8): a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial. *Lancet Oncol*, 2018, 19, s. 510–520.
- 10 Long, G. V. – Hauschild, A. – Santinami, M., et al.: Adjuvant dabrafenib plus trametinib in stage III BRAF-mutated melanoma. *N Engl J Med*, 2017, 377, s. 1813–1823.
- 11 Garbe, C. – Amaral, T. – Peris, K., et al.: European consensus-based interdisciplinary guideline for melanoma. Part 2: Treatment – Update 2019. *Eur J Cancer*, 2020, 126, s. 159–177.
- 12 Schermer, B. – Franke, V. – Rozeman, E. A., et al.: Surgical removal of the index node marked using magnetic seed localization to assess response to neoadjuvant immunotherapy in patients with stage III melanoma. *Br J Surg*, 2019, 106, s. 519–522.
- 13 Amaria, R. N. – Menzies, A. M. – Burton, E. M., et al.: Neoadjuvant systemic therapy in melanoma: recommendations of the International Neoadjuvant Melanoma Consortium. *Lancet Oncol*, 2019, 20, s. e378–e389.
- 14 Amaria, R. N. – Reddy, S. M. – Tawbi, H. A., et al.: Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma. *Nat Med*, 2018, 24, s. 1649–1654.
- 15 Huang, A. C. – Orlowski, R. J. – Xu, X., et al.: A single dose of neoadjuvant PD-1 blockade predicts clinical outcomes in resectable melanoma. *Nat Med*, 2019, 25, s. 454–461.
- 16 Rozeman, E. A. – Menzies, A. M. – van Akkooi, A. C. J., et al.: Identification of the optimal combination dosing schedule of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma (OpACIN-neo): a multicentre, phase 2, randomised, controlled trial. *Lancet Oncol*, 2019, 20, s. 948–960.
- 17 Long, G. V. – Saw, R. P. M. – Lo, S., et al.: Neoadjuvant dabrafenib combined with trametinib for resectable, stage IIIB–C, BRAFV600 mutation-positive melanoma (NeoCombi): a single-arm, open-label, single-centre, phase 2 trial. *Lancet Oncol*, 2019, 20, s. 961–971.
- 18 Hodi, F. S. – O'Day, S. J. – McDermott, D. F., et al.: Improved survival with ipilimumab in patients with metastatic melanoma. *N Engl J Med*, 2010, 363, s. 711–723.
- 19 Robert, C. – Thomas, L. – Bondarenko, I., et al.: Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. *N Engl J Med*, 2011, 364, s. 2517–2526.
- 20 Ascierto, P. A. – Marincola, F. M. – Ribas, A.: Anti-CTLA4 monoclonal antibodies: the past and the future in clinical application. *J Trans Med*, 2011, 9, s. 196.
- 21 Robert, C. – Long, G. V. – Brady, B., et al.: Nivolumab in previously untreated melanoma without BRAF mutation. *N Engl J Med*, 2015, 372, s. 320–330.
- 22 Ascierto, P. A. – Long, G. V. – Robert, C., et al.: Survival outcomes in patients with previously untreated BRAF wild-type advanced melanoma treated with nivolumab therapy: three-year follow-up of a randomized phase 3 trial. *JAMA Oncol*, 2019, 5, s. 187–194.
- 23 Robert, C. – Schachter, J. – Long, G. V., et al.: Pembrolizumab versus ipilimumab in advanced melanoma. *N Engl J Med*, 2015, 372, s. 2521–2532.
- 24 Schachter, J. – Ribas, A. – Long, G. V., et al.: Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006). *Lancet*, 2017, 390, s. 1853–1862.
- 25 Wolchok, J. D. – Chiarion-Sileni, V. – Gonzalez, R., et al.: Overall survival with combined nivolumab and ipilimumab in advanced melanoma. *N Engl J Med*, 2017, 377, s. 1345–1356.
- 26 Larkin, J. – Chiarion-Sileni, V. – Gonzalez, R., et al.: Five-year survival with combined nivolumab and ipilimumab in advanced melanoma. *N Engl J Med*, 2019, 381, s. 1535–1546.
- 27 Hodi, F. S. – Chiarion-Sileni, V. – Gonzalez, R., et al.: Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial. *Lancet Oncol*, 2018, 19, s. 1480–1492.
- 28 Chapman, P. B. – Hauschild, A. – Robert, C., et al.: Improved survival with vemurafenib in melanoma with BRAF V600E mutation. *N Engl J Med*, 2011, 364, s. 2507–2516.
- 29 Chapman, P. B. – Robert, C. – Larkin, J., et al.: Vemurafenib in patients with BRAF V600 mutation-positive metastatic melanoma: final overall survival results of the randomized BRIM-3 study. *Ann Oncol*, 2017, 28, s. 2581–2587.
- 30 Hauschild, A. – Grob, J. J. – Demidov, L. V., et al.: Dabrafenib in BRAF-mutated metastatic melanoma: A multicentre, open-label, phase 3 randomised controlled trial. *Lancet*, 2012, 380, s. 358–365.
- 31 Villanueva, J. – Vultur, A. – Herlyn, M.: Resistance to BRAF inhibitors: unravelling mechanisms and future treatment options. *Cancer Res*, 2011, 71, s. 7137–7140.
- 32 Kakadia, S. – Yarlagadda, N. – Awad, R., et al.: Mechanisms of resistance to BRAF and MEK inhibitors and clinical update of US Food and Drug Administration-approved targeted therapy in advanced melanoma. *Onco Targets Ther*, 2018, 11, s. 7095–7107.
- 33 Robert, C. – Grob, J. J. – Stroyakovskiy, D., et al.: Five-year outcomes with dabrafenib plus trametinib in metastatic melanoma. *N Engl J Med*, 2019, 381, s. 626–636.
- 34 Ascierto, P. A. – McArthur, G. A. – Dréno, B., et al.: Cobimetinib combined with vemurafenib in advanced BRAFV600-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial. *Lancet Oncol*, 2016, 17, s. 1248–1260.
- 35 Dummer, R. – Ascierto, P. A. – Gogas, H. J., et al.: Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trial. *Lancet Oncol*, 2018, 19, s. 1315–1327.
- 36 Long, G. V. – Grob, J. J. – Nathan, P., et al.: Factors predictive of response, disease progression, and overall survival after dabrafenib and trametinib combination treatment: a pooled analysis of individual patient data from randomised trials. *Lancet Oncol*, 2016, 17, s. 1743–1754.
- 37 Long, G. V. – Lebbe, C. – Atkinson, V., et al.: The anti-PD-1 antibody spartalizumab (S) in combination with dabrafenib (D) and trametinib (T) in previously untreated patients (pts) with advanced BRAF V600-mutant melanoma: Updated efficacy and safety from parts 1 and 2 of COMBI-H. *J Clin Oncol*, 2019, 37, suppl. 15, s. 9531–9531.
- 38 Nathan, P. – Dummer, R. – Long, G. V., et al.: Melanoma and other skin tumours. LBA43 Spartalizumab plus dabrafenib and trametinib (Sparta-DabTram) in patients (pts) with previously untreated BRAF V600-mutant unresectable or metastatic melanoma: Results from the randomized part 3 of the phase III COMBI-H trial. Dostupné z: <https://doi.org/10.1016/j.jannonc.2020.08.2273>, vyhledáno 5. 9. 2022.
- 39 Tsai, K. K. – Zarosso, I. – Daud, A. I.: PD-1 and PD-L1 antibodies for melanoma. *Hum Vaccines Immunother*, 2014, 10, s. 3111–3116.
- 40 Sullivan, R. J. – Hamid, O. – Gonzalez, R., et al.: Atezolizumab plus cobimetinib and vemurafenib in BRAF-mutated melanoma patients. *Nat Med*, 2019, s. 929–935.
- 41 Zhang, M. – Yan, Z. – Wang, J., et al.: Toll-like receptors 7 and 8 expression correlates with the expression of immune biomarkers and positively predicts the clinical outcome of patients with melanoma. *Onco Targets Ther*, 2017, 10, s. 4339–4346.
- 42 Klemen, N. D. – Feingold, P. L. – Goff, S. L., et al.: Metastectomy following immunotherapy with adoptive cell transfer for patients with advanced melanoma. *Ann Surg Oncol*, 2017, 24, s. 135–141.
- 43 Lauss, M. – Donia, M. – Harbst, K., et al.: Mutational and putative neoantigen load predict clinical benefit of adoptive T cell therapy in melanoma. *Nat Commun*, 2017, 8, s. 1738.
- 44 Sobin, L. H. – Gospodarowicz, M. K. – Wittekind, Ch.: TNF klasifikace zhoubných nádorů. 2009, česká verze 2011. Wiley-Blackwell. UICC – International Union Against Cancer, dostupné z: <https://www.uizs.cz/sites/default/files/knihovna/tnm-7.pdf>, vyhledáno 5. 9. 2022.

# Nové cesty konzervativní léčby děložních myomů

doc. MUDr. Eduard Kučera, CSc. Gynekologické pracoviště Polikliniky Prahy 7

- 1 Reis, F. M. – Bloise, E. – Ortiga-Carvalho, T. M.: Hormones and pathogenesis of uterine fibroids. *Best Pract Res Clin Obstet Gynaecol*, 2016, 34, s. 13–24.
- 2 Borahay, M. A. – Asoglu, M. R. – Mas, A., et al.: Estrogen receptors and signaling in fibroids: role in pathobiology and therapeutic implications. *Reprod Sci*, 2017, 24, s. 1235–1244.
- 3 Bulun, S. E. – Imir, G. – Utsunomiya, H., et al.: Aromatase in endometriosis and uterine leiomyomata. *J Steroid Biochem Mol Biol*, 2005, 95, s. 57–62.
- 4 Sabry, M. – Al-Hendy, A.: Medical treatments of uterine leiomyoma. *Reprod Sci*, 2012, 19, s. 339–353.
- 5 Palomba, S. – Sammartino, A. – Di Carlo, C., et al.: Effects of raloxifene treatment on uterine leiomyomas in postmenopausal women. *Fertil Steril*, 2001, 76, s. 38–43.
- 6 Premkumar, A. – Venzon, D. J. – Avila, N., et al.: Gynecologic and hormonal effects of raloxifene in premenopausal women. *Fertil Steril*, 2007, 88, s. 1637–1644.
- 7 Murji, A. – Whitaker, L. – Chow, T. L., et al.: Selective progesterone receptor modulators (SPRMs) for uterine fibroids. *Cochrane Database Syst Rev*, 2017, 4, s. CD010770.
- 8 Shaikh, N. – Mehra, R. – Goel, P., et al.: Mifepristone in fibroids: comparative study of safety and efficacy of biweekly dosage vs daily dosage schedule. *J Midlife Health*, 2021, 12, s. 39–45.
- 9 Trefoux Bourdet, A. – Luton, D. – Koskas, M.: Clinical utility of ulipristal acetate for the treatment of uterine fibroids: current evidence. *Int J Womens Health*, 2015, 26, s. 321–330.
- 10 Ciebiera, M. – Vitale, S. G. – Ferrero, S., et al.: Vilaprisan, a new selective progesterone receptor modulator in uterine fibroid pharmacotherapy-will it really be a breakthrough? *Curr Pharm Des*, 2020, 26, s. 300–309.
- 11 Struthers, R. S. – Nicholls, A. J. – Grundy, J., et al.: Suppression of gonadotropins and estradiol in premenopausal women by oral administration of the nonpeptide gonadotropin-releasing hormone antagonist elagolix. *J Clin Endocrinol Metab*, 2009, 94, s. 545–551.
- 12 Al-Hendy, A. – Lukes, A. S. – Poindexter, A. N. 3rd., et al.: Treatment of uterine fibroid symptoms with relugolix combination therapy. *N Engl J Med*, 2021, 384, s. 630–642.
- 13 Varelas, F. K. – Papanicolaou, A. N. – Vavatsi-Christaki, N., et al.: The effect of anastrozole on symptomatic uterine leiomyomata. *Obstet Gynecol*, 2007, 110, s. 643–649.
- 14 Brakta, S. – Diamond, J. S. – Al-Hendy, A., et al.: Role of vitamin D in uterine fibroid biology. *Fertil Steril*, 2015, 104, s. 698–706.
- 15 Hajhashemi, M. – Ansari, M. – Haghollahi, F., et al.: The effect of vitamin D supplementation on the size of uterine leiomyoma in women with vitamin D deficiency. *Caspian J Intern Med*, 2019, 10, s. 125–131.
- 16 Sabry, M. – Halder, S. K. – Allah, A. S., et al.: Serum vitamin D3 level inversely correlates with uterine fibroid volume in different ethnic groups: a cross-sectional observational study. *Int J Womens Health*, 2013, 5, s. 93–100.
- 17 Ciebiera, M. – Włodarczyk, M. – Ciebiera, M., et al.: Vitamin D and uterine fibroids-review of the literature and novel concepts. *Int J Mol Sci*, 2018, 19, s. 2051.
- 18 Porcaro, G. – Santamaria, A. – Giordano, D., et al.: Vitamin D plus epigallocatechin gallate: a novel promising approach for uterine myomas. *Eur Rev Med Pharmacol Sci*, 2020, 24, s. 3344–3351.
- 19 Yang, Ch. – Lee, J. N. – Hsu, S. C., et al.: Effect of hormone replacement therapy on uterine fibroids in postmenopausal women – a 3-year study. *Maturitas*, 2002, 43, s. 35–39.
- 20 Colacurci, N. – De Franciscis, P. – Cobellis, L., et al.: Effects of hormone replacement therapy on postmenopausal uterine myoma. *Maturitas*, 2000, 35, s. 167–173.
- 21 Gregoriou, O. – Konidaris, S. – Botsis, D., et al.: Long term effects of tibolone on postmenopausal women with uterine myomas. *Maturitas*, 2001, 40, s. 95–99.

# Gastrointestinální stromální nádor – novinky v léčbě pokročilých forem

MUDr. Zdeněk Linke Onkologická klinika 2. LF UK a FN v Motole, Praha

- 1 Blanke, C. – Demetri, G., et al.: Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. *N Engl J Med*, 2002, 347, s. 472–480.
- 2 Data on file, Novartis UK Ltd. Study No STI571B2222. Open, randomized, phase II study of Gleevec in patients with unresectable or metastatic malignant gastrointestinal stromal tumors expressing c-kit. Reportováno 15. 12. 2003.
- 3 Verweij, J. – Casali, P. G. – Zalcberg, J., et al.: Progression free survival in gastrointestinal stromal tumor with high a low dose imatinib: randomised trial. *Lancet*, 2004, 364, s. 1127–1134.
- 4 Bouchet, S. – Poulette, S. – Titier, K., et al.: Relationship between imatinib trough concentration and outcomes in the treatment of advanced gastrointestinal stromal tumours in a real-life setting. *Eur J Cancer*, 2016, 57, s. 31–38.
- 5 Rankin, C. – Von Mehren, M. – Blanke, C., et al.: Dose effect of imatinib in patients with metastatic GIST: Phase III Sarcoma Group Study S0033. *J Clin Oncol*, 2004, suppl. 14, s. 9005–9005.
- 6 Van Glabbeke, M. – Verweij, J., et al.: Initial and late resistance to imatinib in advanced gastro-intestinal stromal tumor are predicted by different prognostic factors, an eortc-igsg-agitg study. *J Clin Oncol*, 2005, 23, s. 5795–5804.
- 7 Blay, J. Y. – Le Cesne, A., et al.: Prospective multicenter randomized phase III study of imatinib in patients with advanced gastrointestinal stromal tumors comparing interruption versus continuation of treatment beyond 1 year: The French Sarcoma Group. *J Clin Oncol*, 2007, 25, s. 1107–1113.
- 8 Rios, M. – La Cesne, A., et al.: Interruption of imatinib in GIST patients with advanced disease after one year of treatment: Updated results of the prospective French Sarcoma Group randomized phase III trial on long term survival. *ASCO Ann Meet*, 2007, abstrakt 10016.
- 9 Van Glabbeke, M. M. – Owzar, K. – Rankin, C., et al.: Comparison of two doses of imatinib for the treatment of unresectable or metastatic gastrointestinal stromal tumors (GIST): A meta – metaanalysis based on 1.640 patients. *J Clin Oncol*, 2010, 28, s. 1247–1253.
- 10 Cioffi, J. P., et al.: Higher imatinib dose better in GIST pts with mutation exon 9. *Eur J Cancer*, 2006, 42, s. 1093–1103.
- 11 Demetri, G. D. – van Oosterom, A. T., et al.: Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. *Lancet*, 2006, s. 6736–6746.
- 12 Heinrich, M. C. – Maki, R. G. – Corless, C. L., et al.: Sunitinib response in imatinib-resistant GIST correlates with KIT and PDGFRA mutation status. *J Clin Oncol*, 2006, 24, suppl., abstrakt 9502.
- 13 Demetri, G. D. – Reichardt, P. – Kang, K.-Y., et al.: Randomized phase III trial of regorafenib in patients (pts) with metastatic and/or unresectable gastrointestinal stromal tumor (GIST) progressing despite prior treatment with at least imatinib (IM) and sunitinib (SU): GRID Trial. *J Clin Oncol*, 2012, 30, suppl. 18.
- 14 Von Mehren, M. – Tetzlaff, E. D. – Macarage, M., et al.: Dose escalating study of crenolanib besylate in advanced GIST patients with PDGFR D842V activating mutation. *J Clin Oncol*, 2016, 34, suppl. 15.
- 15 A Study of olaratumab (IMC-3G3) in previously treated participants with unresectable and/or metastatic gastrointestinal stromal tumors. Dostupné z: <https://clinicaltrials.gov/ct2/show/results/NCT01316263>, vyhledáno 6. 9. 2022.
- 16 Shapiro, G. I. – LoRusso, P. – Kwak, E., et al.: Phase Ib study of the MEK inhibitor cobimetinib (GDC-0973) in combination with the PI3K inhibitor pictilisib (GDC-0941) in patients with advanced solid tumors. *Invest New Drugs*, 2020, 38, s. 419–432.
- 17 An Open-label, Phase I, Dose-Escalation Study Evaluating the Safety, Tolerability, and Maximally Tolerated Dose of GDC-0980 Administered Once Daily in Patients With Refractory Solid Tumors and Non-Hodgkin's Lymphoma. Dostupné z: <https://www.knowcancer.com/cancer-trials/NCT00854152/>, vyhledáno 7. 9. 2022.
- 18 Olivier, M. – Cropet, C. – Toulmonde, M., et al.: Pazopanib plus best supportive care versus best supportive care alone in advanced gastrointestinal stromal tumours resistant to imatinib and sunitinib (PAZOGIST): a randomised, multicentre, open-label phase 2 trial. *Lancet Oncol*, 2016, 17, s. 632–641.
- 19 Schoffski, P. – Mir, O. – Kassoer, B., et al.: Activity and safety of cabozantinib in patients with gastrointestinal stromal tumor after failure of imatinib and sunitinib: EORTC phase II trial 1317 CaboGIST. *Eur J Cancer*, 2020, 134, s. 62–74.
- 20 Heinrich, M. – Jones, R. L. – von Mehren, M., et al.: Clinical activity of BLU-285, a highly potent and selective KIT/PDGFRα inhibitor designed to treat gastrointestinal stromal tumor (GIST). Prezentováno na: Annual Meeting of the Connective Tissue Oncology Society, 2017. Maui, HI. Přednáška (#2803523).
- 21 Dostupné z: <https://www.gistsupport.org/treatments/clinical-trials/navigator-trial-avapritinib-results/>, vyhledáno 6. 9. 2022.
- 22 A clinical trial of avapritinib versus regorafenib (Stivarga®) for people with advanced GIST that has progressed following first-line treatment with imatinib (Gleevec®) and one or two additional treatment regimens (third-line or fourth-line GIST). Dostupné z: <https://www.blueprintclinicaltrials.com/clinical-trial/voyager/#about-arrowPhase3>, vyhledáno 6. 9. 2022.
- 23 Study of DCC-2618 vs placebo in advanced GIST patients who have been treated with prior anticancer therapies (INVICTUS). Dostupné z: <https://clinicaltrials.gov/ct2/show/NCT03353753>, vyhledáno 6. 9. 2022.
- 24 Dostupné z: <https://www.gistsupport.org/about-gist/sdh-deficient-amp-wildtype-gist/>, vyhledáno 6. 9. 2022.
- 25 Falchook, G. S., et al.: BRAF mutant gastrointestinal stromal tumor: first report of regression with BRAF inhibitor dabrafenib (GSK 2118436) and whole exome sequencing for analysis of acquired resistance. *Oncotarget*, 2013, 4, s. 310–315.
- 26 Toulmonde, M. – Penel, N. – Adam, J., et al.: Use of PD-L1 targeting, macrophage infiltration, and IDO pathway activation in sarcomas. *JAMA Oncol*, 2018, 4, s. 93–97.
- 27 Kang, Y. K. – Ryu, M. H. – Yoo, C., et al.: Resumption of imatinib to control metastatic or unresectable gastrointestinal stromal tumours after failure of imatinib and sunitinib (RIGHT): a randomised, placebo controlled, phase 3 trial. *Lancet Oncol*, 2013, 14, s. 1175–1182.
- 28 Kang, Y. – George, S. – Jones, R. L., et al.: Avapritinib versus regorafenib in locally advanced unresectable or metastatic GI stromal tumor: a randomized, open-label phase III study. *J Clin Oncol*, 2021, 39, s. 3128–3139.
- 29 Mir, O. – Brodowicz, T. – Italiano, A., et al.: Safety and efficacy of regorafenib in patients with advanced soft tissue sarcoma (REGOSARC): a randomised, double-blind, placebo-controlled, phase 2 trial. *Lancet Oncol*, 2016, 17, s. 1732–1742.

# Léčebné konopí v klinické praxi

doc. MUDr. Jiří Slíva, Ph.D. Ústav farmakologie 3. LF UK, Praha

- 1 Rohleder, C. – Müller, J. K.: Pharmakologie von Cannabis und Cannabinoiden. *PPT*, 2020, 27, s. 105–113, dostupné z: [https://www.ppt-online.de/\\_Resources/Persistent/d/2/4/5/d2452fdb-c972206edc59d17deef249c99cad0/ppt202003\\_artikel1574.pdf](https://www.ppt-online.de/_Resources/Persistent/d/2/4/5/d2452fdb-c972206edc59d17deef249c99cad0/ppt202003_artikel1574.pdf), vyhledáno 22. 11. 2022.
- 2 Ferber, S. G. – Namdar, D. – Hen-Shoval, D., et al.: The „Entourage Effect“: terpenes coupled with cannabinoids for the treatment of mood disorders and anxiety disorders. *Curr Neuropharmacol*, 2020, 18, s. 87–96.
- 3 Koltai, H., et al.: Promoting cannabis products to pharmaceutical drugs. *Eur J Pharm Sci*, 2019, 132, s. 118–120.
- 4 McPartland, J. M. – Pruitt, P. L.: Side effects of pharmaceuticals not elicited by comparable herbal medicines: the case of tetrahydrocannabinol and marijuana. *Altern Ther Health Med*, 1999, 5, s. 57–62.
- 5 Russo, E. B.: The case for the entourage effect and conventional breeding of clinical cannabis: no „strain“, no gain. *Front Plant Sci*, 2019, 9, s. 1969.
- 6 Lewis, M. A. – Russo, E. B. – Smith, K. M.: Pharmacological foundations of cannabis chemovars. *Planta Med*, 2018, 84, s. 225–233.
- 7 Atakan, Z.: Cannabis, a complex plant: different compounds and different effects on individuals. *Ther Adv Psychopharmacol*, 2012, 2, s. 241–254.

# Nechirurgická terapie karcinomu močového měchýře

MUDr. Miroslav Hodek, Ph.D. Klinika onkologie a radioterapie FN a LF UK v Hradci Králové

- 1 Teoh, J. Y.-Ch. – Huang, J. – Ko, W. Y.-K., et al.: Global trends of bladder cancer incidence and mortality, and their associations with tobacco use and gross domestic product per capita. *Eur Urol*, 2020, 78, s. 893–906.
- 2 Advanced Bladder Cancer (ABC) Meta-analysis Collaboration: Neoadjuvant chemotherapy in invasive bladder cancer: update of a systematic review and meta-analysis of individual patient data advanced bladder cancer (ABC) meta-analysis collaboration. *Eur Urol*, 2005, 48, s. 202–205; discussion s. 205–206.
- 3 Powles, T., et al.: Bladder cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. *Ann Oncol*, 2022, 33, s. 244–258.
- 4 Leow, J. J., et al.: Adjuvant chemotherapy for invasive bladder cancer: a 2013 updated systematic review and meta-analysis of randomized trials. *Eur Urol*, 2014, 66, s. 42–54.
- 5 Sternberg, C. N., et al.: Immediate versus deferred chemotherapy after radical cystectomy in patients with pT3-pT4 or N+ M0 urothelial carcinoma of the bladder (EORTC 30994): an intergroup, open-label, randomised phase 3 trial. *Lancet Oncol*, 2015, 16, s. 76–86.
- 6 Witjes, J. A., et al.: European association of urology guidelines on muscle-invasive and metastatic bladder cancer: summary of the 2020 guidelines. *Eur Urol*, 2021, 79, s. 82–104.
- 7 Bajorin, D. F., et al.: Adjuvant nivolumab versus placebo in muscle-invasive urothelial carcinoma. *N Engl J Med*, 2021, 384, s. 2102–2114.
- 8 Fiaig, T. W., et al.: NCCN Guidelines (R) Insights: Bladder Cancer, Version 2.2022. *J Natl Compr Canc Netw*, 2022, 20, s. 866–878.
- 9 von der Maase, H., et al.: Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinorelbine, doxorubicin, plus cisplatin in patients with bladder cancer. *J Clin Oncol*, 2005, 23, s. 4602–4608.
- 10 De Santis, M., et al.: Randomized phase II/III trial assessing gemcitabine/carboplatin and methotrexate/carboplatin/vinorelbine in patients with advanced urothelial cancer who are unfit for cisplatin-based chemotherapy: EORTC study 30986. *J Clin Oncol*, 2012, 30, s. 191–199.
- 11 Powles, T., et al.: Avelumab maintenance therapy for advanced or metastatic urothelial carcinoma. *N Engl J Med*, 2020, 383, s. 1218–1230.
- 12 Bellmunt, J., et al.: Pembrolizumab as second-line therapy for advanced urothelial carcinoma. *N Engl J Med*, 2017, 376, s. 1015–1026.
- 13 Balar, A. V., et al.: First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study. *Lancet Oncol*, 2017, 18, s. 1483–1492.
- 14 Powles, T., et al.: Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial. *Lancet Oncol*, 2021, 22, s. 931–945.
- 15 Balar, A. V., et al.: Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial. *Lancet*, 2017, 389, s. 67–76.
- 16 Siefker-Radtke, A. O., et al.: Efficacy and safety of erdafitinib in patients with locally advanced or metastatic urothelial carcinoma: long-term follow-up of a phase 2 study. *Lancet Oncol*, 2022, 23, s. 248–258.
- 17 Powles, T., et al.: Enfortumab vedotin in previously treated advanced urothelial carcinoma. *N Engl J Med*, 2021, 384, s. 1125–1135.
- 18 Tagawa, S. T., et al.: TROPHY-U-01: A phase II open-label study of sacituzumab govitecan in patients with metastatic urothelial carcinoma progressing after platinum-based chemotherapy and checkpoint inhibitors. *J Clin Oncol*, 2021, 39, s. 2474–2485.
- 19 Galsky, M. D. – Hahn, N. M. – Rosenberg, J., et al.: A consensus definition of patients with metastatic urothelial carcinoma who are unfit for cisplatin-based chemotherapy. *Lancet Oncol*, 2011, 12.

## Fixní kombinace aklidiniumu bromidu s formoteroli fumarátem v léčbě chronické obstrukční plicní nemoci

doc. MUDr. Jiří Slíva, Ph.D. Ústav farmakologie 3. LF UK, Praha

- 1 Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global Strategy for the Diagnosis, Management and Prevention of Chronic Obstructive Pulmonary Disease: 2021 Report. Dostupné z: [www.goldcopd.org](http://www.goldcopd.org), vyhledáno 12. 6. 2022.
- 2 Sullivan, J. – Pravosud, V. – Mannino, D. M., et al.: National and state estimates of COPD morbidity and mortality – United States, 2014–2015. *Chronic Obstr Pulm Dis*, 2018, 5, s. 324–333.
- 3 World Health Organization (WHO). Chronic obstructive pulmonary disease. Dostupné z: [https://www.who.int/news-room/fact-sheets/detail/chronic-obstructive-pulmonary-disease-\(copd\)](https://www.who.int/news-room/fact-sheets/detail/chronic-obstructive-pulmonary-disease-(copd)), vyhledáno 12. 6. 2022.
- 4 Rennard, S. I. – Vestbo, J.: COPD: the dangerous underestimate of 15%. *Lancet*, 2006, 367, s. 1216–1219.
- 5 Nic, L. – Mammen, M. J. – Charbek, E., et al.: Pharmacologic management of chronic obstructive pulmonary disease. An Official American Thoracic Society Clinical Practice Guideline. *Am J Respir Crit Care Med*, 2020, 201, s. e56–e69.
- 6 D'Urzo, A. D. – Singh, D. – Donohue, J. F., et al.: Acclidinium bromide/formoterol fumarate as a treatment for COPD: an update. *Expert Rev Respir Med*, 2021, 15, s. 1093–1106.
- 7 Bateman, E. D. – Chapman, K. R. – Singh, D., et al.: Acclidinium bromide and formoterol fumarate as a fixed-dose combination in COPD: pooled analysis of symptoms and exacerbations from two six-month, multicentre, randomised studies (ACLIFORM and AUGMENT). *Respir Res*, 2015, 16, s. 92.
- 8 D'Urzo, A. D. – Singh, D. – Donohue, J. F., et al.: Efficacy of acclidinium/formoterol 400/12 µg, analyzed by air flow obstruction severity, age, sex, and exacerbation history: pooled analysis of ACLIFORM and AUGMENT. *Int J Chron Obstruct Pulmon Dis*, 2019, 14, s. 479–491.
- 9 Singh, D. – Jones, P. W. – Bateman, E. D.: Efficacy and safety of acclidinium bromide/formoterol fumarate fixed-dose combinations compared with individual components and placebo in patients with COPD (ACLIFORM-COPD): a multicentre, randomised study. *BMC Pulm Med*, 2014, 14, s. 178.
- 10 Sethi, S. – Kerwin, E. – Watz, H., et al.: AMPLIFY: a randomized, Phase III study evaluating the efficacy and safety of acclidinium/formoterol vs monocomponents and tiotropium in patients with moderate-to-very severe symptomatic COPD. *Int J Chron Obstruct Pulmon Dis*, 2019, 14, s. 667–682.
- 11 Plate, T. – Friedrich, F. W. – Beier, J.: Effectiveness and tolerability of LABA/LAMA fixed-dose combinations acclidinium/formoterol, glycopyrronium/indacaterol and umecclidinium/vilanterol in the treatment of COPD in daily practice – results of the non-interventional DETECT Study. *Int J Chron Obstruct Pulmon Dis*, 2020, 15, s. 1335–1347.
- 12 Domnik, N. J. – James, M. D. – Scheeren, R. E., et al.: Deterioration of nighttime respiratory mechanics in COPD: impact of bronchodilator therapy. *Chest*, 2021, 159, s. 116–127.
- 13 Watz, H. – Troosters, T. – Beeh, K. M., et al.: ACTIVATE: the effect of acclidinium/formoterol on hyperinflation, exercise capacity, and physical activity in patients with COPD. *Int J Chron Obstruct Pulmon Dis*, 2017, 12, s. 2545–2558.
- 14 Wise, R. A. – Chapman, K. R. – Scirica, B. M.: Effect of acclidinium bromide on major cardiovascular events and exacerbations in high-risk patients with chronic obstructive pulmonary disease: The ASCENT-COPD randomized clinical trial. *JAMA*, 2019, 321, s. 1693–1701.
- 15 Kerwin, E. – Rennard, S. I. – Gelb, A. F., et al.: Twice-daily acclidinium bromide in COPD patients: night-time symptoms and rescue medication use in ACCORD COPD 1. *Am J Respir Crit Care Med*, 2011, 183, A1592.

## Výběr inhalačních steroidů v léčbě astmatu na základě terapeutického indexu

MUDr. Iva Pončáková Centrum alergologie a klinické imunologie Nemocnice Na Homolce, Praha

- 1 Bousquet, J. – Mantzouranis, E. – Cruz, A. A., et al.: Uniform definition of asthma severity, control, and exacerbations: document presented for the World Health Organization Consultation on Severe Asthma. *J Allergy Clin Immunol*, 2010, 126, s. 926–938.
- 2 GINA (Global Initiative for Asthma). Global Strategy for Asthma Management and Prevention, 2014. Dostupné z: <http://www.ginasthma.org>.
- 3 Reddel, H. K. – Taylor, D. R. – Bateman, E. D., et al.: American Thoracic Society/European Respiratory Society Task Force on Asthma Control and Exacerbations: An official American Thoracic Society/European Respiratory Society statement: asthma control and exacerbations: standardizing endpoints for clinical asthma trials and clinical practice. *Am J Respir Crit Care Med*, 2009, 180, s. 59–99.
- 4 Sims, E. J. – Price, D. – Haughney, J., et al.: Current control and future risk in asthma management. *Allergy Asthma Immunol Res*, 2011, 3, s. 217–225.
- 5 Chung, K. F. – Wenzel, S. E. – Brozek, J. L., et al.: International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. *Eur Respir J*, 2014, 43, s. 343–373.
- 6 Global Initiative for Asthma. Global strategy for asthma management and prevention 2009 update. Dostupné z: <https://ginasthma.org/wp-content/uploads/2019/01/2009-GINA.pdf>, vyhledáno 26. 9. 2022.
- 7 Louis, R. – Schleich, F. – Barnes, P. J.: Corticosteroids. Still at the front-line in asthma treatment? *Clin Chest Med*, 2012, 33, s. 531–541.
- 8 Kašák, V.: *Asthma bronchiale – průvodce ošetřujícího lékaře*. Praha, Maxdorf Jessenius, 2013, s. 140–152.
- 9 Barnes, P. J.: Scientific rationale for inhaled combination therapy with long-acting β<sub>2</sub>-agonists and corticosteroids. *EUR Respir J*, 2002, 19, s. 182–189.
- 10 Kočí, T. – Kašák, V. – Pohunek, P., et al.: *Strategie diagnostiky, prevence a léčby astmatu*. Praha, Jalta, 2012, s. 90.
- 11 Teřil, M. – Čáp, P. – Dvořáková, R., et al.: Doporučený postup diagnostiky a léčby bronchiálního astmatu. ČPFS, ČSAKI, ČSPD 2014. Dostupné z: [www.pneumologie.cz](http://www.pneumologie.cz).
- 12 Teřil, M.: Současné možnosti léčby těžkého astmatu v ČR. *Remedia* 2012. Dostupné z: <http://www.remedia.cz/Okruhy-temat/Alergologie/Soucasne-moznosti-lecby-tezkeho-astmatu-v-CR-8-Q-1kf-magarticle.aspx>, vyhledáno 23. 9. 2022.
- 13 Kašák, V.: *Asthma bronchiale*. Praha, Jessenius/Maxdorf, 2005.
- 14 Saag, K. G. – Furst, D. E. – Barnes, P. J.: Major side effects if inhaled glucocorticoids. Dostupné z: <http://www.uptodate.com/contents/major-side-effects-of-inhaled-glucocorticoids>, vyhledáno 23. 9. 2022.
- 15 Babu, K. S. – Gadzik, F. – Holgate, S. T.: Absence of respiratory effects with ivabradine in patients with asthma. *Br J Clin Pharmacol*, 2008, 66, s. 96–101.
- 16 McGhen, R. M.: Airway disease: Corticosteroids. In: Albert, R. – Spiro, S. – Jett, J.: *Clinical Respiratory Medicine*. Mosby, 2008, s. 483–489.
- 17 Barnes, P.: How corticosteroids control inflammation. *Br J Pharmacol*, 2006, 148, s. 245–254.
- 18 Horvath, G. – Wanner, A.: Inhaled corticosteroids: effects on the airway vasculature in bronchial asthma. *Eur Respir J*, 2006, 27, s. 172–187.
- 19 Daley-Yates, P. – Brealey, N. – Thomas, S., et al.: Therapeutic index of inhaled corticosteroids in asthma: A dose–response comparison on airway hyperresponsiveness and adrenal axis suppression. *Br J Clin Pharmacol*, 2021, 87, s. 483–493.
- 20 Allen, A. – Bareille, P. J. – Rousell, V. M.: Fluticasone furoate, a novel inhaled corticosteroid, demonstrated prolonged lung absorption kinetics in man compared with inhaled fluticasone propionate. *Clin Pharmacokinet*, 2013, 52, s. 37–42.
- 21 Derendorf, H. – Meltzer, E.: Molecular and clinical pharmacology of intranasal corticosteroids: clinical and therapeutic implications. *Allergy*, 2008, 63, s. 1292–1300.
- 22 Barnes, P. J.: Inhaled corticosteroids. *Pharmaceuticals*, 2010, 3, s. 514–540.

# Farmakodynamické a farmakokinetické aspekty terapie přímými perorálními antikoagulanty

PharmDr. Alena Pilková | PharmDr. Jan Miroslav Hartinger, Ph.D.

Oddělení klinické farmakologie a farmacie, Farmakologický ústav 1. LF UK a VFN, Praha

- Ingrasciotta, Y. – Crisafulli, S. – Pizzimenti, V., et al.: Pharmacokinetics of new oral anticoagulants: implications for use in routine care. *Expert Opin Drug Metab Toxicol*, 2018, 14, s. 1057–1069.
- Steffel, J. – Collins, R. – Antz, M., et al.: 2021 European Heart Rhythm Association practical guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. *EP Europace*, 2021, 23, s. 1612–1676.
- IBM Micromedex. In: Greenwood Village (CO): IBM Corporation.
- Ashley, C. – Dunleavy, A.: *The Renal Drug Handbook*. Boca Raton, FL, USA, CRC Press, 2019.
- Mueck, W. – Stampfuss, J. – Kubitzka, D., et al.: Clinical pharmacokinetic and pharmacodynamic profile of rivaroxaban. *Clin Pharmacokinet*, 2014, 53, s. 1–16.
- Byon, W. – Garonzik, S. – Boyd, R. A., et al.: Apixaban: a clinical pharmacokinetic and pharmacodynamic review. *Clin Pharmacokinet*, 2019, 58, s. 1265–1279.
- Stangier, J.: Clinical pharmacokinetics and pharmacodynamics of the oral direct thrombin inhibitor dabigatran etexilate. *Clin Pharmacokinet*, 2008, 47, s. 285–295.
- Peterson, J. J. – Hoehns, J. D.: Administration of direct oral anticoagulants through enteral feeding tubes. *J Pharm Technol*, 2016, 2016, s. 196–200.
- Hartinger, M. – Dvořáčková, E.: Lékové interakce u pacientů s onemocněním ledvin. *Postgraduální nefrologie*, 2019, 17, s. 34–37.
- Vrijens, B. – Heidbuchel, H.: Non-vitamin K antagonist oral anticoagulants: considerations on once- vs. twice-daily regimens and their potential impact on medication adherence. *EP Europace*, 2015, 17, s. 514–523.
- Vrijens, B. – Claeys, M. J. – Legrand, V., et al.: Projected inhibition of platelet aggregation with ticagrelor twice daily vs. clopidogrel once daily based on patient adherence data (the TWICE project). *Br J Clin Pharmacol*, 2014, 77, s. 746–755.
- Hindricks, G. – Potpara, T. – Dagres, N., et al.: 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. *Eur Heart J*, 2021, 42, s. 373–498.
- Aboyans, V. – Ricco, J.-B. – Bartelink, M.-L. E. L., et al.: 2017 ESC Guidelines on the Diagnosis and Treatment of Peripheral Arterial Diseases, in collaboration with the European Society for Vascular Surgery (ESVS): Document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteries. Endorsed by: the European Stroke Organization (ESO) The Task Force for the Diagnosis and Treatment of Peripheral Arterial Diseases of the European Society of Cardiology (ESC) and of the European Society for Vascular Surgery (ESVS). *Eur Heart J*, 2017, 39, s. 763–816.
- Collet, J.-P. – Thiele, H. – Barbato, E., et al.: 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: The Task Force for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). *Eur Heart J*, 2020, 42, s. 1289–1367.
- Ibanez, B. – James, S. – Agewall, S., et al.: 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). *Eur Heart J*, 2017, 39, s. 119–177.
- Platná SPC. Dostupná z Databáze léků, www.sukl.cz. Státní ústav pro kontrolu léčiv.
- Vazquez, S. R.: Drug-drug interactions in an era of multiple anticoagulants: a focus on clinically relevant drug interactions. *Blood*, 2018, 132, s. 2230–2239.
- Härtter, S. – Sennewald, R. – Nehmiz, G., et al.: Oral bioavailability of dabigatran etexilate (Pradaxa) after co-medication with verapamil in healthy subjects. *Br J Clin Pharmacol*, 2013, 75, s. 1053–1062.
- Wiggins, B. S. – Dixon, D. L. – Neyens, R. R., et al.: Select drug-drug interactions with direct oral anticoagulants: JACC review topic of the week. *J Am Coll Cardiol*, 2020, 75, s. 1341–1350.
- Hughes, S. – Szeki, I. – Nash, M. J., et al.: Anticoagulation in chronic kidney disease patients – the practical aspects. *Clin Kidney J*, 2014, 7, s. 442–449.
- Rychlík, I.: *Budoucnost farmakoterapie v nefrologii*. Mladá fronta, 2015.
- Turpie, A. G. G. – Purdham, D. – Ciaccia, A.: Nonvitamin K antagonist oral anticoagulant use in patients with renal impairment. *Thromb Res Cardiovasc Dis*, 2017, 11, s. 243–256.
- Jain, N. – Reilly, R. F.: Clinical pharmacology of oral anticoagulants in patients with kidney disease. *Clin J Am Soc Nephrol*, 2018.
- Shin, J. I. – Secora, A. – Alexander, G. C., et al.: Risks and benefits of direct oral anticoagulants across the spectrum of GFR among incident and prevalent patients with atrial fibrillation. *Clin J Am Soc Nephrol*, 2018, 13, s. 1144–1152.
- Kubitzka, D. – Roth, A. – Becka, M., et al.: Effect of hepatic impairment on the pharmacokinetics and pharmacodynamics of a single dose of rivaroxaban, an oral, direct Factor Xa inhibitor. *Br J Clin Pharmacol*, 2013, 76, s. 89–98.
- Stangier, J. – Stähle, H. – Rathgen, K., et al.: Pharmacokinetics and pharmacodynamics of dabigatran etexilate, an oral direct thrombin inhibitor, are not affected by moderate hepatic impairment. *J Clin Pharmacol*, 2008, 48, s. 1411–1419.
- Ballestri, S. – Capitelli, M. – Fontana, M. C., et al.: Direct oral anticoagulants in patients with liver disease in the era of non-alcoholic fatty liver disease global epidemic: a narrative review. *Adv Ther*, 2020, 37, s. 1910–1932.
- Pilková, A. – Hartinger, M. J.: Změny farmakokinetiky léčiv u obézních pacientů. *Vnitřní lékařství*, 2020, 66, s. 465–471.
- Rocca, B. – Fox, K. A. A. – Aijan, R. A., et al.: Antithrombotic therapy and body mass: an expert position paper of the ESC Working Group on Thrombosis. *Eur Heart J*, 2018, 39, s. 1672–1686.
- Güler, E. – Babur Güler, G. – Demir, G. G., et al.: A review of the fixed dose use of new oral anticoagulants in obese patients: Is it really enough? *Anatol J Cardiol*, 2015, 15, s. 1020–1029.
- Reilly, P. A. – Lehr, T. – Haertter, S., et al.: The effect of dabigatran plasma concentrations and patient characteristics on the frequency of ischemic stroke and major bleeding in atrial fibrillation patients: the RE-LY Trial (Randomized Evaluation of Long-Term Anticoagulation Therapy). *J Am Coll Cardiol*, 2014, 63, s. 321–328.
- Balla, S. R. – Cyr, D. D. – Lokhnygina, Y., et al.: Relation of risk of stroke in patients with atrial fibrillation to body mass index (from patients treated with rivaroxaban and warfarin in the rivaroxaban once daily oral direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation trial). *Am J Cardiol*, 2017, 119, s. 1989–1996.
- Berger, J. S. – Libalberté, F. – Kharat, A., et al.: Real-world effectiveness and safety of rivaroxaban versus warfarin among non-valvular atrial fibrillation patients with obesity in a US population. *Curr Med Res Opin*, 2021, 37, s. 881–890.
- Hohnloser, S. H. – Fudim, M. – Alexander, J. H., et al.: Efficacy and safety of apixaban versus warfarin in patients with atrial fibrillation and extremes in body weight. *Circulation*, 2019, 139, s. 2292–2300.
- Sandhu, R. K. – Ezekowitz, J. – Andersson, U., et al.: The 'obesity paradox' in atrial fibrillation: observations from the ARISTOTLE (apixaban for reduction in stroke and other thromboembolic events in atrial fibrillation) trial. *Eur Heart J*, 2016, 37, s. 2869–2878.
- Boriani, G. – Ruff, C. T. – Kuder, J. F., et al.: Relationship between body mass index and outcomes in patients with atrial fibrillation treated with edoxaban or warfarin in the ENGAGE AF-TIMI 48 trial. *Eur Heart J*, 2019, 40, s. 1541–1550.
- Boriani, G. – Ruff, C. T. – Kuder, J. F., et al.: Edoxaban versus warfarin in patients with atrial fibrillation at the extremes of body weight: an analysis from the ENGAGE AF-TIMI 48 trial. *Thromb Haemost*, 2021, 121, s. 140–149.
- Mocini, D. – Di Fusco, S. A. – Mocini, E., et al.: Direct oral anticoagulants in patients with obesity and atrial fibrillation: position paper of Italian National Association of Hospital Cardiologists (ANMCO). *J Clin Med*, 2021, 10.
- Kubitzka, D. – Becka, M. – Zuehlsdorf, M., et al.: Body weight has limited influence on the safety, tolerability, pharmacokinetics, or pharmacodynamics of rivaroxaban (BAY 59-7939) in healthy subjects. *J Clin Pharmacol*, 2007, 47, s. 218–226.
- Upreti, V. V. – Wang, J. – Barrett, Y. C., et al.: Effect of extremes of body weight on the pharmacokinetics, pharmacodynamics, safety and tolerability of apixaban in healthy subjects. *Br J Clin Pharmacol*, 2013, 76, s. 908–916.
- Ruff, C. T. – Giugliano, R. P. – Braunwald, E., et al.: Association between edoxaban dose, concentration, anti-Factor Xa activity, and outcomes: an analysis of data from the randomised, double-blind ENGAGE AF-TIMI 48 trial. *Lancet*, 2015, 385, s. 2288–2295.
- Stangier, J. – Rathgen, K. – Stähle, H., et al.: The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects. *Br J Clin Pharmacol*, 2007, 64, s. 292–303.
- Eikelboom, J. W. – van Ryn, J. – Reilly, P., et al.: Dabigatran reversal with idarucizumab in patients with renal impairment. *J Am Coll Cardiol*, 2019, 74, s. 1760–1768.
- Pollack, C. V. Jr. – Reilly, P. A. – van Ryn, J., et al.: Idarucizumab for dabigatran reversal – full cohort analysis. *N Engl J Med*, 2017, 377, s. 431–441.
- Tomaselli, G. F. – Mahaffey, K. W. – Cuker, A., et al.: 2020 ACC expert consensus decision pathway on management of bleeding in patients on oral anticoagulants: a report of the American College of Cardiology Solution Set Oversight Committee. *J Am Coll Cardiol*, 2020, 76, s. 594–622.
- Connolly, S. J. – Crowther, M. – Eikelboom, J. W., et al.: Full study report of andexanet alfa for bleeding associated with factor Xa inhibitors. *N Engl J Med*, 2019, 380, s. 1326–1335.

## Inzulín Toujeo jako opora každodenního života pacientů s diabetem mellitus – výsledky studie InRange a ULTRAFLEXI 1

MUDr. Kateřina Himmellová, MBA Diabetologie-endokrinologie Hi-dent, s. r. o., Ostrava

Mgr. Petr Srnc, MBA Fakulta tělesné kultury, Katedra přírodních věd v kinantropologii, Univerzita Palackého, Olomouc

- Pelikánová, T. – Bartoš, V., et al.: *Praktická diabetologie*. Maxdorf Jesenius, Praha, 2018, s. 60.
- Pelikánová, T. – Bartoš, V., et al.: *Praktická diabetologie*. Maxdorf Jesenius, Praha, 2018, s. 13.
- Horová, E. – Breburdová, M. – Fejfarová, V., et al.: Česká diabetologická společnost: Doporučení pro fyzickou aktivitu u diabetem mellitus České diabetologické společnosti ČLS JEP. Dostupné z: [https://www.diab.cz/dokumenty/doporučení\\_postup\\_fyz\\_aktivita.pdf](https://www.diab.cz/dokumenty/doporučení_postup_fyz_aktivita.pdf), vyhledáno 30. 10. 2022.
- Lachin, J. M. – Bebu, I. – Nathan, D. M., et al.: The beneficial effects of earlier versus later implementation of intensive therapy in type 1 diabetes. *Diabetes Care*, 2021, 44, s. 2225–2230.
- Beck, R. W. – Riddlesworth, T. – Ruedy, K., et al.: Effect of continuous glucose monitoring on glycemic control in adults with type 1 diabetes using insulin injections: the DIAMOND randomized clinical trial. *JAMA*, 2017, 317, s. 371–378.
- Toujeo, SPC, 9. 7. 2020. Dostupné z: <https://www.sukl.cz>
- Battelino, T. – Danne, T. – Edelman, S. V., et al.: Continuous glucose monitoring-based time-in-range using insulin glargine 300 units/ml versus insulin degludec 100 units/ml in type 1 diabetes: The head-to-head randomized controlled InRange trial. *Diabetes Obes Metab*, 2022, doi: 10.1111/dom.14898.
- Moser, O. – Mueller, A. – Aberer, F., et al.: 39-LB: A comparison of insulin glargine U300 and insulin degludec around spontaneous exercise sessions in people with type 1 diabetes—The ULTRAFLEXI-1 Study. *Diabetes*, 2022, 71, suppl. 1, s. 39-LB, doi.org/10.2337/db22-39-LB.
- Garber, C. E. – Blissmer, B. – Deschenes, M. R., et al.: American College of Sports Medicine position stand. Quantity and quality of exercise for developing and maintaining cardiorespiratory, musculoskeletal, and neuromotor fitness in apparently healthy adults: guidance for prescribing exercise. *Med Sci Sports Exerc*, 2011, 43, s. 1334–1359.
- Jelleyman, C. – Yates, T. – O'Donovan, G., et al.: The effects of high-intensity interval training on glucose regulation and insulin resistance: a meta-analysis. *Obesity Reviews*, 2015, s. 942–961, doi.org/10.1111/obr.12317.

# Potenciál fixních kombinací nejen v diabetologii se zaměřením na empagliflozin

doc. MUDr. Jiří Slíva, Ph.D. Ústav farmakologie 3. LF UK, Praha

- Gautam, C. S. – Saha, L.: Fixed dose drug combinations (FDCs): rational or irrational: a view point. *Br J Clin Pharmacol*, 2008, 65, s. 795–796.
- Bangalore, S. – Kamalakkannan, G. – Parkar, S., et al.: Fixed-dose combinations improve medication compliance: a meta-analysis. *Am J Med*, 2007, 120, s. 713–719.
- Saenz, A. – Fernandez-Esteban, I. – Mataix, A., et al.: Metformin monotherapy for type 2 diabetes mellitus. *Cochrane Database Syst Rev*, 2005, CD002966.
- Formoso, G. – De Filippis, E. A. – Michetti, N., et al.: Decreased in vivo oxidative stress and decreased platelet activation following metformin treatment in newly diagnosed type 2 diabetic subjects. *Diabetes Metab Res Rev*, 2008, 24, s. 231–237.
- Detaille, D. – Guigas, B. – Chauvin, C., et al.: Metformin prevents high-glucose-induced endothelial cell death through a mitochondrial permeability transition-dependent process. *Diabetes*, 2005, 54, s. 2179–2187.
- Scarpello, J. H. – Howlett, H. C.: Metformin therapy and clinical uses. *Diab Vasc Dis Res*, 2008, 5, s. 157–167.
- Scheen, A. J.: Pharmacokinetic and pharmacodynamic profile of empagliflozin, a sodium glucose co-transporter 2 inhibitor. *Clin Pharmacokinet*, 2014, 53, s. 213–225.
- Ferrannini, E. – Muscelli, E. – Frascerra, S., et al.: Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients. *J Clin Invest*, 2013, 124, s. 499–508.
- DeFronzo, R. A. – Lewin, A. – Patel, S., et al.: Combination of empagliflozin and linagliptin as second-line therapy in subjects with type 2 diabetes inadequately controlled on metformin. *Diabetes Care*, 2015, 38, s. 384–393.
- Blevins, T.: Combination therapy for patients with uncontrolled type 2 diabetes mellitus: adding empagliflozin to pioglitazone or pioglitazone plus metformin. *Expert Opin Drug Saf*, 2015, 14, s. 789–793.
- Kovacs, C. S. – Seshiah, V. – Merker, L., et al.: Empagliflozin as add-on therapy to pioglitazone with or without metformin in patients with type 2 diabetes. *Clin Ther*, 2015, 37, s. 1773–1788.
- Rosenstock, J. – Seman, L. J. – Jelaska, A., et al.: Efficacy and safety of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, as add-on to metformin in type 2 diabetes with mild hyperglycaemia. *Diabetes Obes Metab*, 2013, 15, s. 1154–1160.
- Ridderstrale, M. – Andersen, K. R. – Zeller, C., et al.: Comparison of empagliflozin and glimepiride as add-on to metformin in patients with type 2 diabetes: a 104-week randomised, active-controlled, double-blind, phase 3 trial. *Lancet Diabetes Endocrinol*, 2014, 2, s. 691–700.
- Ferrannini, E. – Berk, A. – Hantel, S., et al.: Long-term safety and efficacy of empagliflozin, sitagliptin, and metformin: an active-controlled, parallel-group, randomized, 78-week open-label extension study in patients with type 2 diabetes. *Diabetes Care*, 2013, 36, s. 4015–4021.
- Haring, H. U. – Merker, L. – Seewaldt-Becker, E., et al.: Empagliflozin as add-on to metformin in patients with type 2 diabetes: a 24-week, randomized, double-blind, placebo-controlled trial. *Diabetes Care*, 2014, 37, s. 1650–1659.
- Haring, H. U. – Merker, L. – Seewaldt-Becker, E., et al.: Empagliflozin as add-on to metformin plus sulfonylurea in patients with type 2 diabetes: a 24-week, randomized, double-blind, placebo-controlled trial. *Diabetes Care*, 2013, 36, s. 3396–3404.
- Kovacs, C. S. – Seshiah, V. – Swallow, R., et al.: Empagliflozin improves glycaemic and weight control as add-on therapy to pioglitazone or pioglitazone plus metformin in patients with type 2 diabetes: a 24-week, randomized, placebo-controlled trial. *Diabetes Obes Metab*, 2014, 16, s. 147–158.
- Ross, S. – Thamer, C. – Cescutti, J., et al.: Efficacy and safety of empagliflozin twice daily versus once daily in patients with type 2 diabetes inadequately controlled on metformin: a 16-week, randomized, placebo-controlled trial. *Diabetes Obes Metab*, 2015, 17, s. 699–702.
- Merker, L. – Haring, H. U. – Christiansen, A. V., et al.: Empagliflozin as add-on to metformin in people with type 2 diabetes. *Diabet Med*, 2015, 32, s. 1555–1567.
- Haering, H. U. – Merker, L. – Christiansen, A. V., et al.: Empagliflozin as add-on to metformin plus sulphonylurea in patients with type 2 diabetes. *Diabetes Res Clin Pract*, 2015, 110, s. 82–90.
- Zhong, X. – Lai, D. – Ye, Y., et al.: Efficacy and safety of empagliflozin as add-on to metformin for type 2 diabetes: a systematic review and meta-analysis. *Eur J Clin Pharmacol*, 2016, 72, s. 655–663.

## Ixekizumab – význam v léčbě axiální spondyloartritidy

MUDr. Olga Kryšřtřfková, Ph.D. Revmatologický ústav, Praha

- Benucci, M. – Damiani, A. – Li Gobbi, F., et al.: Therapeutic potential of ixekizumab in the treatment of ankylosing spondylitis: a review on the emerging clinical data. *Ther Clin Risk Manag*, 2020, 16, s. 287–297.
- Osta, B. – Lavocat, F. – Eljaafari, A., et al.: Effects of interleukin-17A on osteogenic differentiation of isolated human mesenchymal stem cells. *Front Immunol*, 2014, 5, s. 425.
- Poddubnyy, D. – Sieper, J.: Mechanism of new bone formation in axial spondyloarthritis. *Curr Rheumatol Rep*, 2017, 19, s. 55.
- Dougados, M. – Wei, J. C.-C. – Landewé, R., et al.: Efficacy and safety of ixekizumab through 52 weeks in two phase 3, randomised, controlled clinical trials in patients with active radiographic axial spondyloarthritis (COAST-V and COAST-W). *Ann Rheum Dis*, 2020, 79, s. 176–185.
- Deodhar, A. – van der Heijde, D. – Gensler, L. S., et al.: Ixekizumab for patients with non-radiographic axial spondyloarthritis (COAST-X): a randomised, placebo-controlled trial. *Lancet*, 2020, 395, s. 53–64.
- Landewé, R. B. M. – Gensler, L. S. – Poddubnyy, D., et al.: Continuing versus withdrawing ixekizumab treatment in patients with axial spondyloarthritis who achieved remission: efficacy and safety results from a placebo-controlled, randomised withdrawal study (COAST-Y). *Ann Rheum Dis*, 2021, 80, s. 1022–1030.
- Braun, J. – Kiltz, U. – Deodhar, A., et al.: Efficacy and safety of ixekizumab treatment in patients with axial spondyloarthritis: 2-year results from COAST. *RMD Open*, 2022, 8, s. e002165.
- Deodhar, A. – Poddubnyy, D. – Rahman, P., et al.: Safety and efficacy of ixekizumab treatment in patients with axial spondyloarthritis: 3-year clinical trial results from the COAST program. *Ann Rheum Dis*, 2022, 81, suppl. 1, s. 765.
- van der Heijde, D. – Østergaard, M. – Reveille, J. D., et al.: Spinal radiographic progression and predictors of progression in patients with radiographic axial spondyloarthritis receiving ixekizumab over 2 years. *J Rheumatol*, 2022, 49, s. 265–273.
- Ramiro, S. – Lukas, C. – Nissen, M. J., et al.: Efficacy and improvement in patient reported outcomes at weeks 16 and 52 in ixekizumab treated biological naive patients with radiographic axial spondyloarthritis achieving clinically important painat night reduction at week 16: results from Coast-V trial. *Ann Rheum Dis*, 2021, 80, suppl. 1, s. 765–766.
- Magrey, M. – De Vlam, K. – Kronbergs, A., et al.: Efficacy of ixekizumab through 52 weeks for improving peripheral joint involvement among patients with radiographic-axial spondyloarthritis. *Ann Rheum Dis*, 2021, 80, suppl. 1, s. 713.